Tenaya TherapeuticsTNYA
TNYA
About: Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
Employees: 97
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
291% more call options, than puts
Call options by funds: $137K | Put options by funds: $35K
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
12.01% less ownership
Funds ownership: 31.23% [Q1] → 19.22% (-12.01%) [Q2]
17% less funds holding
Funds holding: 105 [Q1] → 87 (-18) [Q2]
30% less capital invested
Capital invested by funds: $27.5M [Q1] → $19.1M (-$8.32M) [Q2]
45% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 38
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
718%
upside
Avg. target
$9
718%
upside
High target
$9
718%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Geulah Livshits | 718%upside $9 | Buy Maintained | 7 Aug 2025 |
Financial journalist opinion
Based on 4 articles about TNYA published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET.
Neutral
The Motley Fool
2 weeks ago
Tenaya (TNYA) Q2 Loss Narrows 59%
Tenaya Therapeutics (TNYA -2.99%), a clinical-stage biotechnology company focused on genetic therapies for heart disease, released second-quarter results on August 6, 2025. Tenaya posted a net loss per share of $(0.14) (GAAP) for Q2 2025, narrower than the $(0.19) loss analysts had predicted.
Neutral
GlobeNewsWire
2 weeks ago
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™ -1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts
Neutral
GlobeNewsWire
3 weeks ago
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025
Neutral
GlobeNewsWire
3 months ago
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 461,000 shares of Tenaya common stock to three new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of $0.4373 per share, which is equal to the closing price of Tenaya's common stock on May 15, 2025. Each stock option has a ten-year term and vests as follows over a total of four years: 1/4th of the original number of shares subject to the stock option shall vest on the one-year anniversary of the employee's date of hire and 1/48th of the original number of shares subject to the stock option shall vest every month thereafter, subject to such employee's continued service with Tenaya on each such date.
Neutral
GlobeNewsWire
3 months ago
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease
Neutral
GlobeNewsWire
4 months ago
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene
Neutral
GlobeNewsWire
4 months ago
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25 SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced that interim data from the first three patients enrolled in the company's MyPEAK-1 Phase 1b/2 clinical trial of TN-201 were highlighted in a Late-Breaker presentation at the 2025 American College of Cardiology Scientific Sessions (ACC.25).
Neutral
GlobeNewsWire
5 months ago
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publications of positive preclinical data for TN-201, the company's gene therapy candidate for Myosin-Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), in Nature Communications.
Neutral
GlobeNewsWire
5 months ago
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session
Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201
Charts implemented using Lightweight Charts™